SARS-CoV-2 Spike Glycoprotein S2
To Order Contact us: [email protected]
SARS-CoV-2 Spike Glycoprotein |
|||
| abx600065-200g | Abbexa | 200 µg | EUR 4187.5 |
SARS-CoV-2 Spike Glycoprotein |
|||
| abx600065-50g | Abbexa | 50 µg | EUR 312.5 |
SARS-CoV-2 Spike Glycoprotein |
|||
| abx620076-100g | Abbexa | 100 µg | EUR 287.5 |
SARS-CoV-2 Spike Glycoprotein |
|||
| abx620076-1mg | Abbexa | 1 mg | EUR 1700 |
SARS-CoV-2 Spike Glycoprotein |
|||
| abx620076-200g | Abbexa | 200 µg | EUR 412.5 |
Sars-CoV-2 Spike Glycoprotein S2 (SF9 cell line) |
|||
| MBS669426-005mg | MyBiosource | 0.05mg | EUR 1240 |
Sars-CoV-2 Spike Glycoprotein S2 (SF9 cell line) |
|||
| MBS669426-015mg | MyBiosource | 0.15mg | EUR 2610 |
Sars-CoV-2 Spike Glycoprotein S2 (SF9 cell line) |
|||
| MBS669426-5x015mg | MyBiosource | 5x0.15mg | EUR 11730 |
SARS-CoV-2 Spike Glycoprotein S2 SF9 Cell Line |
|||
| T6798 | ABM | 1x10^6 cells/1.0ml | Ask for price |
SARS-CoV-2 (COVID-19) Spike Glycoprotein-S2, Recombinant protein |
|||
| 39-112 | ProSci | 0.05 mg | EUR 1520.7 |
|
Description: A human infecting coronavirus (viral pneumonia) called 2019 novel coronavirus, 2019-nCoV was found in the fish market at the city of Wuhan, Hubei province of China on December 2019. The 2019-nCoV shares an 87% identity to the 2 bat-derived severe acute respiratory syndrome 2018 SARS-CoV-2 located in Zhoushan of eastern China. 2019-nCoV has an analogous receptor-BD-structure to that of 2018 SARS-CoV, even though there is a.a. diversity so thus the 2019-nCoV might bind to ACE2 receptor protein (angiotensin-converting enzyme 2) in humans. While bats are possibly the host of 2019-nCoV, researchers suspect that animal from the ocean sold at the seafood market was an intermediate host. RSCU analysis proposes that the 2019-nCoV is a recombinant within the viral spike glycoprotein between the bat coronavirus and an unknown coronavirus. |
|||
S glycoprotein | SARS-CoV-2 Spike Glycoprotein (polyclonal) |
|||
| AS20-4372 | Agrisera AB | 50 µg | EUR 302 |
SARS-CoV-2 Spike Glycoprotein (S2), Sheep Fc-Tag (CHO) |
|||
| REC31870-100 | The Native Antigen Company | 0.1 | EUR 500.86 |
|
Description: Recombinant SARS-CoV-2 Spike Glycoprotein S2, C-terminally tagged with a sheep Fc-tag. Protein was produced in CHO cells and purified from culture supernatant by Protein G chromatography. |
|||
SARS-CoV-2 Spike Glycoprotein (S2), Sheep Fc-Tag (CHO) |
|||
| REC31870-500 | The Native Antigen Company | 0.5 | EUR 1903.02 |
|
Description: Recombinant SARS-CoV-2 Spike Glycoprotein S2, C-terminally tagged with a sheep Fc-tag. Protein was produced in CHO cells and purified from culture supernatant by Protein G chromatography. |
|||
SARS-CoV-2 Spike Glycoprotein Antibody |
|||
| abx243125-96tests | Abbexa | 96 tests | EUR 462.5 |
SARS-CoV-2 Spike Glycoprotein Antibody |
|||
| abx243126-96tests | Abbexa | 96 tests | EUR 287.5 |
SARS-CoV-2 Spike Glycoprotein Antibody |
|||
| abx341095-100l | Abbexa | 100 µl | EUR 400 |
SARS-CoV-2 Spike Glycoprotein Antibody |
|||
| abx341095-50l | Abbexa | 50 µl | EUR 287.5 |
SARS-CoV-2 Spike Glycoprotein Antibody |
|||
| abx341096-100l | Abbexa | 100 µl | EUR 400 |
SARS-CoV-2 Spike Glycoprotein Antibody |
|||
| abx341096-50l | Abbexa | 50 µl | EUR 287.5 |
SARS-CoV-2 Spike Glycoprotein Antibody |
|||
| abx341097-100l | Abbexa | 100 µl | EUR 400 |
SARS-CoV-2 Spike Glycoprotein Antibody |
|||
| abx341097-50l | Abbexa | 50 µl | EUR 287.5 |
SARS-CoV-2 Spike Glycoprotein Antibody |
|||
| abx376478-96tests | Abbexa | 96 tests | EUR 300 |
SARS-CoV-2 Spike Glycoprotein Antibody |
|||
| abx376479-96tests | Abbexa | 96 tests | EUR 300 |
SARS-CoV-2 Spike Glycoprotein Antibody |
|||
| abx376524-96tests | Abbexa | 96 tests | EUR 243.75 |
SARS-CoV-2 Spike Glycoprotein Antibody |
|||
| abx345504-01mg | Abbexa | 0.1 mg | EUR 250 |
SARS-CoV-2 Spike Glycoprotein Antibody |
|||
| abx345505-100tests | Abbexa | 100 tests | EUR 250 |
SARS-CoV-2 Spike Glycoprotein Fragment |
|||
| abx620044-100g | Abbexa | 100 µg | EUR 250 |
SARS-CoV-2 Spike Glycoprotein Fragment |
|||
| abx620044-1mg | Abbexa | 1 mg | EUR 1362.5 |
SARS-CoV-2 Spike Glycoprotein Fragment |
|||
| abx620044-200g | Abbexa | 200 µg | EUR 350 |
SARS-CoV-2 Spike Glycoprotein Fragment |
|||
| abx620045-100g | Abbexa | 100 µg | EUR 250 |
SARS-CoV-2 Spike Glycoprotein Fragment |
|||
| abx620045-1mg | Abbexa | 1 mg | EUR 1362.5 |
SARS-CoV-2 Spike Glycoprotein Fragment |
|||
| abx620045-200g | Abbexa | 200 µg | EUR 350 |
SARS-CoV-2 Spike Glycoprotein Fragment |
|||
| abx620046-100g | Abbexa | 100 µg | EUR 250 |
SARS-CoV-2 Spike Glycoprotein Fragment |
|||
| abx620046-1mg | Abbexa | 1 mg | EUR 1362.5 |
SARS-CoV-2 Spike Glycoprotein Fragment |
|||
| abx620046-200g | Abbexa | 200 µg | EUR 350 |
SARS-CoV-2 Spike Glycoprotein Fragment |
|||
| abx620047-100g | Abbexa | 100 µg | EUR 250 |
SARS-CoV-2 Spike Glycoprotein Fragment |
|||
| abx620047-1mg | Abbexa | 1 mg | EUR 1362.5 |
SARS-CoV-2 Spike Glycoprotein Fragment |
|||
| abx620047-200g | Abbexa | 200 µg | EUR 350 |
SARS-CoV-2 Spike Glycoprotein Antibody |
|||
| abx226551-100g | Abbexa | 100 µg | EUR 225 |
SARS-CoV-2 Spike glycoprotein Antibody |
|||
| K06251M01F01C-100ug | Absea Biotechnology | 100 ug | EUR 320 |
|
Description: Monoclonal Antibody |
|||
SARS-CoV-2 Spike glycoprotein Antibody |
|||
| K06251M01F01C-1mg | Absea Biotechnology | 1 mg | EUR 1600 |
|
Description: Monoclonal Antibody |
|||
SARS-CoV-2 Spike glycoprotein Antibody |
|||
| K06251M01F01C-50ug | Absea Biotechnology | 50 ug | EUR 224 |
|
Description: Monoclonal Antibody |
|||
SARS-CoV-2 Spike glycoprotein Antibody |
|||
| K06251M05C05C-100ug | Absea Biotechnology | 100 ug | EUR 320 |
|
Description: Monoclonal Antibody |
|||
SARS-CoV-2 Spike glycoprotein Antibody |
|||
| K06251M05C05C-1mg | Absea Biotechnology | 1 mg | EUR 1600 |
|
Description: Monoclonal Antibody |
|||
SARS-CoV-2 Spike glycoprotein Antibody |
|||
| K06251M05C05C-50ug | Absea Biotechnology | 50 ug | EUR 224 |
|
Description: Monoclonal Antibody |
|||
SARS-CoV-2 Spike glycoprotein Antibody |
|||
| K06251M06A06C-100ug | Absea Biotechnology | 100 ug | EUR 320 |
|
Description: Monoclonal Antibody |
|||
SARS-CoV-2 Spike glycoprotein Antibody |
|||
| K06251M06A06C-1mg | Absea Biotechnology | 1 mg | EUR 1600 |
|
Description: Monoclonal Antibody |
|||
SARS-CoV-2 Spike glycoprotein Antibody |
|||
| K06251M06A06C-50ug | Absea Biotechnology | 50 ug | EUR 224 |
|
Description: Monoclonal Antibody |
|||
SARS-CoV-2 Spike Glycoprotein (S2), Sheep Fc-Tag (HEK293) |
|||
| REC31807-100 | The Native Antigen Company | 0.1 | EUR 500.86 |
|
Description: Recombinant SARS-CoV-2 S2 glycoprotein (NCBI accession number YP_009724390.1, AA676-1211), C-terminally tagged with a dimeric sheep Fc-tag. Protein was produced in HEK293 cells and purified from culture supernatant by Protein G chromatography. |
|||
SARS-CoV-2 Spike Glycoprotein (S2), Sheep Fc-Tag (HEK293) |
|||
| REC31807-500 | The Native Antigen Company | 0.5 | EUR 1903.02 |
|
Description: Recombinant SARS-CoV-2 (NCBI accession number YP_009724390.1, AA676-1211), C-terminally tagged with a dimeric sheep Fc-tag. Protein was produced in HEK293 cells and purified from culture supernatant by Protein G chromatography. |
|||
SARS-CoV-2 Spike Glycoprotein (S2), His-Tag (Insect Cells) |
|||
| REC31830-100 | The Native Antigen Company | 0.1 | EUR 464.81 |
|
Description: Recombinant SARS-CoV-2 Spike S2 protein was produced in T. ni cells by infection with a recombinant baculovirus and purified from culture supernatant by immobilised metal affinity and ion exchange chromatography. |
|||
SARS-CoV-2 Spike Glycoprotein (S2), His-Tag (Insect Cells) |
|||
| REC31830-500 | The Native Antigen Company | 0.5 | EUR 1766.54 |
|
Description: Recombinant SARS-CoV-2 Spike S2 protein was produced in T. ni cells by infection with a recombinant baculovirus and purified from culture supernatant by immobilised metal affinity and ion exchange chromatography. |
|||
Recombinant SARS-CoV Spike glycoprotein |
|||
| MBS1560493-005mg | MyBiosource | 0.05mg | EUR 310 |
Recombinant SARS-CoV Spike glycoprotein |
|||
| MBS1560493-01mg | MyBiosource | 0.1mg | EUR 400 |
Recombinant SARS-CoV Spike glycoprotein |
|||
| MBS1560493-1mg | MyBiosource | 1mg | EUR 1465 |
Recombinant SARS-CoV Spike glycoprotein |
|||
| MBS1560493-5x1mg | MyBiosource | 5x1mg | EUR 6265 |
SARS-CoV-2 Spike Glycoprotein-S2, Recombinant protein Fc Tag |
|||
| ICOV2SPIKEGLYS2RFC50UG | Innovative research | each | EUR 1912 |
|
Description: SARS-CoV-2 Spike Glycoprotein-S2, Recombinant protein Fc Tag |
|||
SARS-CoV-2 Spike Glycoprotein-S2, Recombinant protein Fc Tag |
|||
| MBS8430889-INQUIRE | MyBiosource | INQUIRE | Ask for price |
SARS-CoV-2 Spike glycoprotein ELISA Kit |
|||
| DEIASL018 | Creative Diagnostics | 96T | EUR 1310.4 |
|
Description: Cell culture supernates, plasma |
|||
SARS-CoV-2 spike glycoprotein S1 protein |
|||
| 30-2008 | Fitzgerald Industries International | 500 ug | Ask for price |
SARS-CoV-2 spike glycoprotein RBD protein |
|||
| 30-2011 | Fitzgerald Industries International | 500 ug | Ask for price |
SARS-CoV-2 Spike Glycoprotein Antibody (HRP) |
|||
| abx243127-96tests | Abbexa | 96 tests | EUR 287.5 |
SARS-CoV-2 Spike Glycoprotein RBD Nanobody |
|||
| abx243130-96tests | Abbexa | 96 tests | EUR 462.5 |
SARS-CoV-2 Spike Glycoprotein Antibody (HRP) |
|||
| abx345506-01mg | Abbexa | 0.1 mg | EUR 250 |
SARS-CoV-2 Spike Glycoprotein Antibody (HRP) |
|||
| abx345507-100tests | Abbexa | 100 tests | EUR 250 |
SARS-CoV-2 Spike Glycoprotein Antibody (FITC) |
|||
| abx243128-96tests | Abbexa | 96 tests | EUR 287.5 |
SARS-CoV-2 Spike Glycoprotein Antibody (FITC) |
|||
| abx345508-01mg | Abbexa | 0.1 mg | EUR 250 |
SARS-CoV-2 Spike Glycoprotein Antibody (FITC) |
|||
| abx345509-100l | Abbexa | 100 µl | EUR 250 |
SARS-CoV-2 Spike Glycoprotein (D614G Mutation) |
|||
| abx169319-100l | Abbexa | 100 µl | EUR 587.5 |
SARS-CoV-2 Spike Glycoprotein (D614G Mutation) |
|||
| abx169319-1ml | Abbexa | 1 ml | Ask for price |
SARS-CoV-2 Spike Glycoprotein (D614G Mutation) |
|||
| abx169319-200l | Abbexa | 200 µl | Ask for price |
Recombinant SARS-CoV-2 Spike Glycoprotein S1 |
|||
| MBS7616025-005mg | MyBiosource | 0.05mg | EUR 560 |
Recombinant SARS-CoV-2 Spike Glycoprotein S1 |
|||
| MBS7616025-02mg | MyBiosource | 0.2mg | EUR 1060 |
Recombinant SARS-CoV-2 Spike Glycoprotein S1 |
|||
| MBS7616025-1mg | MyBiosource | 1mg | EUR 3065 |
Recombinant SARS-CoV-2 Spike Glycoprotein S1 |
|||
| MBS7616025-5x1mg | MyBiosource | 5x1mg | EUR 11850 |
SARS-CoV-2 Spike Glycoprotein Antibody (Biotin) |
|||
| abx243129-96tests | Abbexa | 96 tests | EUR 287.5 |
SARS-CoV-2 Spike Glycoprotein Antibody (Biotin) |
|||
| abx345510-100g | Abbexa | 100 µg | Ask for price |
SARS-CoV-2 Spike Glycoprotein Antibody (Biotin) |
|||
| abx345510-20g | Abbexa | 20 µg | EUR 250 |
SARS-CoV-2 Spike Glycoprotein Antibody (Biotin) |
|||
| abx345510-50g | Abbexa | 50 µg | EUR 350 |
SARS-CoV-2 Spike Glycoprotein Antibody (Biotin) |
|||
| abx345511-100g | Abbexa | 100 µg | Ask for price |
SARS-CoV-2 Spike Glycoprotein Antibody (Biotin) |
|||
| abx345511-20g | Abbexa | 20 µg | EUR 250 |
SARS-CoV-2 Spike Glycoprotein Antibody (Biotin) |
|||
| abx345511-50g | Abbexa | 50 µg | EUR 350 |
SARS-CoV-2 Recombinant Spike Glycoprotein (S1) |
|||
| MBS412776-05mg | MyBiosource | 0.5mg | EUR 3325 |
SARS-CoV-2 Recombinant Spike Glycoprotein (S1) |
|||
| MBS412776-5x05mg | MyBiosource | 5x0.5mg | EUR 14765 |
SARS-CoV-2 Spike Glycoprotein (S2) (aa 800-1000), His-Tag (E. coli) |
|||
| REC31844-100 | The Native Antigen Company | 0.1 | EUR 415.88 |
|
Description: Recombinant protein containing Spike immunodominant region (amino acids 800 to 1000), manufactured to high purity in E. coli. |
|||
SARS-CoV-2 Spike Glycoprotein (S2) (aa 800-1000), His-Tag (E. coli) |
|||
| REC31844-500 | The Native Antigen Company | 0.5 | EUR 1560.53 |
|
Description: Recombinant protein containing Spike immunodominant region (amino acids 800 to 1000), manufactured to high purity in E. coli. |
|||
SARS-CoV-2 Spike Glycoprotein (S2) (aa 1000-1200), His-Tag (E. coli) |
|||
| REC31846-100 | The Native Antigen Company | 0.1 | EUR 415.88 |
|
Description: Recombinant protein containing Spike immunodominant region (aa 1000 to 1200), manufactured to high purity in E. coli. |
|||
SARS-CoV-2 Spike Glycoprotein (S2) (aa 1000-1200), His-Tag (E. coli) |
|||
| REC31846-500 | The Native Antigen Company | 0.5 | EUR 1560.53 |
|
Description: Recombinant protein containing Spike immunodominant region (aa 1000 to 1200), manufactured to high purity in E. coli. |
|||
SARS-CoV-2 Spike Glycoprotein RBD Nanobody (HRP) |
|||
| abx402247-100g | Abbexa | 100 µg | EUR 462.5 |
SARS-CoV-2 Spike Glycoprotein HEK293 Cell Line |
|||
| T6792 | ABM | 1x10^6 cells / 1.0 ml | EUR 3950 |
SARS-CoV-2 Spike Glycoprotein RBD Antibody Pair |
|||
| abx243136-96tests | Abbexa | 96 tests | EUR 950 |
SARS-CoV-2 Spike Glycoprotein RBD Nanobody (FITC) |
|||
| abx402248-100g | Abbexa | 100 µg | EUR 462.5 |
SARS-CoV-2 Spike Glycoprotein RBD Nanobody (Biotin) |
|||
| abx402249-100tests | Abbexa | 100 tests | EUR 462.5 |
Sars-Cov-2 Spike Glycoprotein S1 (SF9 cell line) |
|||
| MBS669425-005mg | MyBiosource | 0.05mg | EUR 1240 |
Sars-Cov-2 Spike Glycoprotein S1 (SF9 cell line) |
|||
| MBS669425-5x005mg | MyBiosource | 5x0.05mg | EUR 11730 |
SARS-CoV-2 Spike Glycoprotein S1 SF9 Cell Line |
|||
| T6797 | ABM | 1x10^6 cells/1.0ml | Ask for price |
SARS-CoV-2 coronavirus spike glycoprotein S1 protein |
|||
| MBS5316641-05mg | MyBiosource | 0.5mg | EUR 1090 |
SARS-CoV-2 coronavirus spike glycoprotein S1 protein |
|||
| MBS5316641-5x05mg | MyBiosource | 5x0.5mg | EUR 4685 |
SARS-CoV-2 coronavirus spike glycoprotein RBD protein |
|||
| MBS5316643-05mg | MyBiosource | 0.5mg | EUR 890 |
SARS-CoV-2 coronavirus spike glycoprotein RBD protein |
|||
| MBS5316643-5x05mg | MyBiosource | 5x0.5mg | EUR 3790 |
SARS-CoV-2 (COVID-19) Spike Glycoprotein-S1, Recombinant protein |
|||
| 39-111 | ProSci | 0.05 mg | EUR 1520.7 |
|
Description: A human infecting coronavirus (viral pneumonia) called 2019 novel coronavirus, 2019-nCoV was found in the fish market at the city of Wuhan, Hubei province of China on December 2019. The 2019-nCoV shares an 87% identity to the 2 bat-derived severe acute respiratory syndrome 2018 SARS-CoV-2 located in Zhoushan of eastern China. 2019-nCoV has an analogous receptor-BD-structure to that of 2018 SARS-CoV, even though there is a.a. diversity so thus the 2019-nCoV might bind to ACE2 receptor protein (angiotensin-converting enzyme 2) in humans. While bats are possibly the host of 2019-nCoV, researchers suspect that animal from the ocean sold at the seafood market was an intermediate host. RSCU analysis proposes that the 2019-nCoV is a recombinant within the viral spike glycoprotein between the bat coronavirus and an unknown coronavirus. |
|||
SARS-CoV-2 Spike Glycoprotein (Trimeric), His-Tag (CHO) |
|||
| REC31871-100 | The Native Antigen Company | 0.1 | EUR 672.11 |
|
Description: Trimeric SARS-CoV-2 spike protein in prefusion confirmation. C-terminal transmembrane region is replaced with a trimerization domain and a polyhistidine tag. Contains two stabilizing proline mutations and scrambled S1/S2 furin cleavage site (Wrapp et al., 2020). |
|||
SARS-CoV-2 Spike Glycoprotein (Trimeric), His-Tag (CHO) |
|||
| REC31871-1000 | The Native Antigen Company | 0.5 | EUR 4599.17 |
|
Description: Trimeric SARS-CoV-2 spike protein in prefusion confirmation. C-terminal transmembrane region is replaced with a trimerization domain and a polyhistidine tag. Contains two stabilizing proline mutations and scrambled S1/S2 furin cleavage site (Wrapp et al., 2020). |
|||
SARS-CoV-2 Spike Glycoprotein (Trimeric), His-Tag (CHO) |
|||
| REC31871-500 | The Native Antigen Company | 0.5 | EUR 2554.52 |
|
Description: Trimeric SARS-CoV-2 spike protein in prefusion confirmation. C-terminal transmembrane region is replaced with a trimerization domain and a polyhistidine tag. Contains two stabilizing proline mutations and scrambled S1/S2 furin cleavage site (Wrapp et al., 2020). |
|||
OPCA335979-1MG - Recombinant SARS-CoV-2 Spike Glycoprotein |
|||
| OPCA335979-1MG | Aviva Systems Biology | 1mg | EUR 3229 |
OPCA335982-1MG - Recombinant SARS-CoV-2 Spike Glycoprotein |
|||
| OPCA335982-1MG | Aviva Systems Biology | 1mg | EUR 3594 |
OPCA335983-1MG - Recombinant SARS-CoV-2 Spike Glycoprotein |
|||
| OPCA335983-1MG | Aviva Systems Biology | 1mg | EUR 4635 |
OPCA335987-1MG - Recombinant SARS-CoV-2 Spike Glycoprotein |
|||
| OPCA335987-1MG | Aviva Systems Biology | 1mg | EUR 1523 |
SARS-CoV-2 Spike Glycoprotein (S2), Sheep Fc-Tag (HEK293): Horseradish Peroxidase |
|||
| REC31807-HRP-100 | The Native Antigen Company | 0.1 | EUR 600 |
|
Description: Recombinant SARS-CoV-2 Spike Glycoprotein S2 is C-terminally tagged with a dimeric sheep Fc-tag. Protein was produced in HEK293 cells and purified from culture supernatant by Protein G chromatography, and then conjugated to Horseradish peroxidase. |
|||
OPCA335979-100UG - Recombinant SARS-CoV-2 Spike Glycoprotein |
|||
| OPCA335979-100UG | Aviva Systems Biology | 100ug | EUR 1569 |
OPCA335982-100UG - Recombinant SARS-CoV-2 Spike Glycoprotein |
|||
| OPCA335982-100UG | Aviva Systems Biology | 100ug | EUR 545 |
OPCA335982-20UG - Recombinant SARS-CoV-2 Spike Glycoprotein |
|||
| OPCA335982-20UG | Aviva Systems Biology | 20ug | EUR 184 |
OPCA335983-100UG - Recombinant SARS-CoV-2 Spike Glycoprotein |
|||
| OPCA335983-100UG | Aviva Systems Biology | 100ug | EUR 545 |
OPCA335983-20UG - Recombinant SARS-CoV-2 Spike Glycoprotein |
|||
| OPCA335983-20UG | Aviva Systems Biology | 20ug | EUR 232 |
OPCA335987-100UG - Recombinant SARS-CoV-2 Spike Glycoprotein |
|||
| OPCA335987-100UG | Aviva Systems Biology | 100ug | EUR 308 |
SARS-CoV-2 Spike Glycoprotein (S1), Sheep Fc-Tag (CHO) |
|||
| REC31869-100 | The Native Antigen Company | 0.1 | EUR 500.86 |
|
Description: Recombinant SARS-CoV-2 Spike Glycoprotein S1, C-terminally tagged with a sheep Fc-tag. Protein was produced in CHO cells and purified from culture supernatant by Protein G chromatography. |
|||
SARS-CoV-2 Spike Glycoprotein (S1), Sheep Fc-Tag (CHO) |
|||
| REC31869-1000 | The Native Antigen Company | 1 | EUR 1903.02 |
|
Description: Recombinant SARS-CoV-2 Spike Glycoprotein S1, C-terminally tagged with a sheep Fc-tag. Protein was produced in CHO cells and purified from culture supernatant by Protein G chromatography. |
|||
SARS-CoV-2 Spike Glycoprotein (S1), Sheep Fc-Tag (CHO) |
|||
| REC31869-500 | The Native Antigen Company | 0.5 | EUR 1903.02 |
|
Description: Recombinant SARS-CoV-2 Spike Glycoprotein S1, C-terminally tagged with a sheep Fc-tag. Protein was produced in CHO cells and purified from culture supernatant by Protein G chromatography. |
|||
SARS-CoV-2 Spike Glycoprotein (S1), Sheep Fc-Tag (CHO) |
|||
| REC31869-5000 | The Native Antigen Company | 5 | EUR 6661.85 |
|
Description: Recombinant SARS-CoV-2 Spike Glycoprotein S1, C-terminally tagged with a sheep Fc-tag. Protein was produced in CHO cells and purified from culture supernatant by Protein G chromatography. |
|||
SARS-CoV-2 coronavirus Spike glycoprotein S1 (S1 protein) |
|||
| MBS7135932-01mg | MyBiosource | 0.1mg | EUR 185 |
SARS-CoV-2 coronavirus Spike glycoprotein S1 (S1 protein) |
|||
| MBS7135932-05mg | MyBiosource | 0.5mg | EUR 545 |
SARS-CoV-2 coronavirus Spike glycoprotein S1 (S1 protein) |
|||
| MBS7135932-1mg | MyBiosource | 1mg | EUR 945 |
SARS-CoV-2 coronavirus Spike glycoprotein S1 (S1 protein) |
|||
| MBS7135932-5x1mg | MyBiosource | 5x1mg | EUR 4200 |
SARS-CoV-2 Spike Glycoprotein (S1) RBD, His-Tag (HEK293) |
|||
| REC31882-100 | The Native Antigen Company | 0.1 | EUR 423.61 |
|
Description: SARS-CoV-2 Spike protein receptor binding domain (RBD) produced in HEK293 cells. The protein was purified from culture supernatant by immobilised metal affinity chromatography |
|||
SARS-CoV-2 Spike Glycoprotein (S1) RBD, His-Tag (HEK293) |
|||
| REC31882-500 | The Native Antigen Company | 0.5 | EUR 1614.6 |
|
Description: SARS-CoV-2 Spike protein receptor binding domain (RBD) produced in HEK293 cells. The protein was purified from culture supernatant by immobilised metal affinity chromatography |
|||
Recombinant SARS-CoV-2 Spike Glycoprotein(S) (D614G), Partial |
|||
| E80028 | EpiGentek |
|
|
SARS-CoV-2 coronavirus spike glycoprotein RBD (RBD protein) |
|||
| MBS7135953-01mg | MyBiosource | 0.1mg | EUR 160 |
SARS-CoV-2 coronavirus spike glycoprotein RBD (RBD protein) |
|||
| MBS7135953-05mg | MyBiosource | 0.5mg | EUR 445 |
SARS-CoV-2 coronavirus spike glycoprotein RBD (RBD protein) |
|||
| MBS7135953-1mg | MyBiosource | 1mg | EUR 770 |
SARS-CoV-2 coronavirus spike glycoprotein RBD (RBD protein) |
|||
| MBS7135953-5x1mg | MyBiosource | 5x1mg | EUR 3415 |
SARS-CoV-2 Spike Glycoprotein (S1), Sheep Fc-Tag (HEK293) |
|||
| BSV-COV-PR-26 | BioServUK | 100 ug | EUR 899 |
|
Description: SARS-CoV-2 Spike Glycoprotein (S1), Sheep (Fc-Tag) (HEK293) |
|||
SARS-CoV-2 Spike Glycoprotein (S1), Sheep Fc-Tag (HEK293) |
|||
| BSV-COV-PR-27 | BioServUK | 500 ug | EUR 3150 |
|
Description: SARS-CoV-2 Spike Glycoprotein (S1), Sheep (Fc-Tag) (HEK293) |
|||
SARS-CoV-2 Spike Glycoprotein (S1), Sheep Fc-Tag (HEK293) |
|||
| REC31806-100 | The Native Antigen Company | 0.1 | EUR 500.86 |
|
Description: Recombinant SARS-CoV-2 S1 glycoprotein (NCBI accession number YP_009724390.1, AA1-674), C-terminally tagged with a dimeric sheep Fc-tag. Protein was produced in HEK293 cells and purified from culture supernatant by Protein G chromatography. |
|||
SARS-CoV-2 Spike Glycoprotein (S1), Sheep Fc-Tag (HEK293) |
|||
| REC31806-500 | The Native Antigen Company | 0.5 | EUR 1903.02 |
|
Description: Recombinant SARS-CoV-2 S1 glycoprotein (NCBI accession number YP_009724390.1, AA1-674), C-terminally tagged with a dimeric sheep Fc-tag. Protein was produced in HEK293 cells and purified from culture supernatant by Protein G chromatography. |
|||
SARS-CoV-2 Spike Glycoprotein (S1), His-Tag (Insect Cells) |
|||
| BSV-COV-PR-24 | BioServUK | 100 ug | EUR 835 |
|
Description: SARS-CoV-2 Spike Glycoprotein (S1), (His-Tag) (Insect Cells) (Spike Protein (S1)) |
|||
SARS-CoV-2 Spike Glycoprotein (S1), His-Tag (Insect Cells) |
|||
| BSV-COV-PR-25 | BioServUK | 500 ug | EUR 2922 |
|
Description: SARS-CoV-2 Spike Glycoprotein (S1), (His-Tag) (Insect Cells) (Spike Protein (S1)) |
|||
SARS-CoV-2 Spike Glycoprotein (S1), His-tag (Insect Cells) |
|||
| REC31828-100 | The Native Antigen Company | 0.1 | EUR 464.81 |
|
Description: Recombinant SARS-CoV-2 Spike Glycoprotein S1, C-terminally tagged with a 6xHis-tag. Protein was produced in insect cells and purified by metal affinity and ion exchange chromatography. |
|||
SARS-CoV-2 Spike Glycoprotein (S1), His-tag (Insect Cells) |
|||
| REC31828-500 | The Native Antigen Company | 0.5 | EUR 1766.54 |
|
Description: Recombinant SARS-CoV-2 Spike Glycoprotein S1, C-terminally tagged with a 6xHis-tag. Protein was produced in insect cells and purified by metal affinity and ion exchange chromatography. |
|||
SARS-CoV-2 Spike Glycoprotein (Full-Length), His-Tag (CHO) |
|||
| REC31868-100 | The Native Antigen Company | 0.1 | EUR 642.49 |
|
Description: Recombinant full-length Spike protein (soluble domain). The furin cleavage site (AA 682-685) has been mutated from RRAR to SRAS and the transmembrane domain and intravirion part was replaced with a glycine-serine linker and a His-tag. |
|||
SARS-CoV-2 Spike Glycoprotein (Full-Length), His-Tag (CHO) |
|||
| REC31868-500 | The Native Antigen Company | 0.5 | EUR 2443.79 |
|
Description: Recombinant full-length Spike protein (soluble domain). The furin cleavage site (AA 682-685) has been mutated from RRAR to SRAS and the transmembrane domain and intravirion part was replaced with a glycine-serine linker and a His-tag. |
|||
Recombinant Human SARS-CoV-2 Spike Glycoprotein S1 RBD (HEK) |
|||
| MBS335825-01mg | MyBiosource | 0.1mg | EUR 615 |
Recombinant Human SARS-CoV-2 Spike Glycoprotein S1 RBD (HEK) |
|||
| MBS335825-5x01mg | MyBiosource | 5x0.1mg | EUR 2770 |
Recombinant SARS-CoV-2 Spike Glycoprotein RBD [Omicron B.1.1.529] |
|||
| MBS7615873-005mg | MyBiosource | 0.05mg | EUR 660 |
Recombinant SARS-CoV-2 Spike Glycoprotein RBD [Omicron B.1.1.529] |
|||
| MBS7615873-02mg | MyBiosource | 0.2mg | EUR 1260 |
Recombinant SARS-CoV-2 Spike Glycoprotein RBD [Omicron B.1.1.529] |
|||
| MBS7615873-1mg | MyBiosource | 1mg | EUR 3670 |
Recombinant SARS-CoV-2 Spike Glycoprotein RBD [Omicron B.1.1.529] |
|||
| MBS7615873-5x1mg | MyBiosource | 5x1mg | EUR 14180 |
SARS-CoV-2 Spike Glycoprotein (Full-Length), His-Tag (HEK293) |
|||
| REC31850-100 | The Native Antigen Company | 0.1 | EUR 500.86 |
|
Description: Recombinant full-length Spike protein (soluble domain). The furin cleavage site (AA 682-685) has been mutated from RRAR to SRAS and the transmembrane domain and intravirion part was replaced with a glycine-serine linker and a His-tag. |
|||
SARS-CoV-2 Spike Glycoprotein (Full-Length), His-Tag (HEK293) |
|||
| REC31850-500 | The Native Antigen Company | 0.5 | EUR 1903.02 |
|
Description: Recombinant full-length Spike protein (soluble domain). The furin cleavage site (AA 682-685) has been mutated from RRAR to SRAS and the transmembrane domain and intravirion part was replaced with a glycine-serine linker and a His-tag. |
|||
SARS-CoV-2 Spike Glycoprotein-S1, Recombinant protein Fc Tag |
|||
| ICOV2SPIKEGLYS1RFC50UG | Innovative research | each | EUR 1912 |
|
Description: SARS-CoV-2 Spike Glycoprotein-S1, Recombinant protein Fc Tag |
|||
SARS-CoV-2 Spike Glycoprotein-S1, Recombinant protein Fc Tag |
|||
| MBS8430888-INQUIRE | MyBiosource | INQUIRE | Ask for price |
Anti SARS-CoV-2 (2019-nCoV) Spike glycoprotein monoclonal Antibody |
|||
| MBS1560485-005mg | MyBiosource | 0.05mg | EUR 275 |
Anti SARS-CoV-2 (2019-nCoV) Spike glycoprotein monoclonal Antibody |
|||
| MBS1560485-01mg | MyBiosource | 0.1mg | EUR 350 |
Anti SARS-CoV-2 (2019-nCoV) Spike glycoprotein monoclonal Antibody |
|||
| MBS1560485-5x01mg | MyBiosource | 5x0.1mg | EUR 1250 |
Anti SARS-CoV-2 (2019-nCoV) Spike glycoprotein monoclonal Antibody |
|||
| MBS1560488-005mg | MyBiosource | 0.05mg | EUR 275 |
Anti SARS-CoV-2 (2019-nCoV) Spike glycoprotein monoclonal Antibody |
|||
| MBS1560488-01mg | MyBiosource | 0.1mg | EUR 350 |
Anti SARS-CoV-2 (2019-nCoV) Spike glycoprotein monoclonal Antibody |
|||
| MBS1560488-5x01mg | MyBiosource | 5x0.1mg | EUR 1250 |
Anti SARS-CoV-2 (2019-nCoV) Spike glycoprotein monoclonal Antibody |
|||
| MBS1560489-005mg | MyBiosource | 0.05mg | EUR 275 |
Anti SARS-CoV-2 (2019-nCoV) Spike glycoprotein monoclonal Antibody |
|||
| MBS1560489-01mg | MyBiosource | 0.1mg | EUR 350 |
Anti SARS-CoV-2 (2019-nCoV) Spike glycoprotein monoclonal Antibody |
|||
| MBS1560489-5x01mg | MyBiosource | 5x0.1mg | EUR 1250 |
SARS-CoV-2 coronavirus spike glycoprotein S1 II (S1 protein II) |
|||
| MBS7137079-01mg | MyBiosource | 0.1mg | EUR 185 |
SARS-CoV-2 coronavirus spike glycoprotein S1 II (S1 protein II) |
|||
| MBS7137079-05mg | MyBiosource | 0.5mg | EUR 545 |
SARS-CoV-2 coronavirus spike glycoprotein S1 II (S1 protein II) |
|||
| MBS7137079-1mg | MyBiosource | 1mg | EUR 945 |
SARS-CoV-2 coronavirus spike glycoprotein S1 II (S1 protein II) |
|||
| MBS7137079-5x1mg | MyBiosource | 5x1mg | EUR 4200 |
SARS-CoV-2 Spike Glycoprotein Rabbit anti-Human Polyclonal Antibody |
|||
| MBS2403884-005mg | MyBiosource | 0.05mg | EUR 615 |
SARS-CoV-2 Spike Glycoprotein Rabbit anti-Human Polyclonal Antibody |
|||
| MBS2403884-5x005mg | MyBiosource | 5x0.05mg | EUR 2605 |
SARS-CoV-2 Spike Glycoprotein Rabbit anti-Human Polyclonal Antibody |
|||
| MBS2403885-005mg | MyBiosource | 0.05mg | EUR 595 |
SARS-CoV-2 Spike Glycoprotein Rabbit anti-Human Polyclonal Antibody |
|||
| MBS2403885-5x005mg | MyBiosource | 5x0.05mg | EUR 2500 |
SARS-CoV-2 Spike Glycoprotein (Trimeric), His-Tag (CHO): HRP Conjugate |
|||
| REC31871-HRP-100 | The Native Antigen Company | 0.1 | EUR 806.01 |
|
Description: Trimeric SARS-CoV-2 spike protein in prefusion confirmation, conjugated to horseradish peroxidase (HRP). C-terminal transmembrane region is replaced with a trimerization domain and a polyhistidine tag. Contains two stabilizing proline mutations and scrambled S1/S2 furin cleavage site (Wrapp et al., 2020). |
|||
SARS-CoV-2 Spike Glycoprotein (Trimeric), His-Tag (CHO): HRP Conjugate |
|||
| REC31871-HRP-500 | The Native Antigen Company | 0.5 | EUR 2822.34 |
|
Description: Trimeric SARS-CoV-2 spike protein in prefusion confirmation, conjugated to horseradish peroxidase (HRP). C-terminal transmembrane region is replaced with a trimerization domain and a polyhistidine tag. Contains two stabilizing proline mutations and scrambled S1/S2 furin cleavage site (Wrapp et al., 2020). |
|||
SARS-CoV-2 (D614G Mutant) Spike Glycoprotein (Trimeric), His-Tag (CHO) |
|||
| REC31898-100 | The Native Antigen Company | 0.1 | EUR 672.11 |
|
Description: Trimeric SARS-CoV-2 spike protein, with D614G mutation, in prefusion confirmation. C-terminal transmembrane region is replaced with a trimerization domain and a polyhistidine tag. Contains two stabilizing proline mutations and scrambled S1/S2 furin cleavage site (Wrapp et al., 2020). |
|||
SARS-CoV-2 (D614G Mutant) Spike Glycoprotein (Trimeric), His-Tag (CHO) |
|||
| REC31898-1000 | The Native Antigen Company | 1 | EUR 4599.17 |
|
Description: Trimeric SARS-CoV-2 spike protein, with D614G mutation, in prefusion confirmation. C-terminal transmembrane region is replaced with a trimerization domain and a polyhistidine tag. Contains two stabilizing proline mutations and scrambled S1/S2 furin cleavage site (Wrapp et al., 2020). |
|||
SARS-CoV-2 (D614G Mutant) Spike Glycoprotein (Trimeric), His-Tag (CHO) |
|||
| REC31898-500 | The Native Antigen Company | 0.5 | EUR 2554.52 |
|
Description: Trimeric SARS-CoV-2 spike protein, with D614G mutation, in prefusion confirmation. C-terminal transmembrane region is replaced with a trimerization domain and a polyhistidine tag. Contains two stabilizing proline mutations and scrambled S1/S2 furin cleavage site (Wrapp et al., 2020). |
|||
SARS-CoV-2 (B.1.1.7) Spike Glycoprotein (Full-Length), His-Tag (HEK293) |
|||
| REC31923-100 | The Native Antigen Company | 0.1 | EUR 642.49 |
|
Description: SARS-CoV-2 Spike protein that contains all amino acid changes of the “UK variant” B.1.1.7 of SARS-CoV-2: 69-70del, Y144del, N501Y, A570D, P681H, T716I, S982A, D1118H relative to Wuhan-Hu-1. This construct has a functional furin cleavage site. |
|||
SARS-CoV-2 (B.1.1.7) Spike Glycoprotein (Full-Length), His-Tag (HEK293) |
|||
| REC31923-500 | The Native Antigen Company | 0.5 | EUR 2443.79 |
|
Description: SARS-CoV-2 Spike protein that contains all amino acid changes of the “UK variant” B.1.1.7 of SARS-CoV-2: 69-70del, Y144del, N501Y, A570D, P681H, T716I, S982A, D1118H relative to Wuhan-Hu-1. This construct has a functional furin cleavage site. |
|||
SARS-CoV-2 (N501Y Mutant) Spike Glycoprotein (S1) RBD, His-Tag (HEK293) |
|||
| REC31946-100 | The Native Antigen Company | 0.1 | EUR 423.61 |
|
Description: SARS-CoV-2 Spike S1 RBD (AA1-223), carrying the N501Y amino acid change. This change is present in all three major global SARS-CoV-2 variants: B.1.1.7, B.1.1.28 and B.1.351. The protein was produced in HEK293 cells and purified from culture supernanant. |
|||
SARS-CoV-2 (N501Y Mutant) Spike Glycoprotein (S1) RBD, His-Tag (HEK293) |
|||
| REC31946-500 | The Native Antigen Company | 0.5 | EUR 1614.6 |
|
Description: SARS-CoV-2 Spike S1 RBD (AA1-223), carrying the N501Y amino acid change. This change is present in all three major global SARS-CoV-2 variants: B.1.1.7, B.1.1.28 and B.1.351. The protein was produced in HEK293 cells and purified from culture supernanant. |
|||
SARS-CoV-2 (D614G Mutant) Spike Glycoprotein (S1), Sheep Fc-Tag (HEK293) |
|||
| REC31883-100 | The Native Antigen Company | 0.1 | EUR 500.86 |
|
Description: Recombinant SARS-CoV-2 Spike Glycoprotein S1 containing the D614G mutation relative to Wuhan-Hu-1. Protein was produced in HEK293 cells and purified from culture supernatant by Protein G chromatography. |
|||
SARS-CoV-2 (D614G Mutant) Spike Glycoprotein (S1), Sheep Fc-Tag (HEK293) |
|||
| REC31883-500 | The Native Antigen Company | 0.5 | EUR 1903.02 |
|
Description: Recombinant SARS-CoV-2 Spike Glycoprotein S1 containing the D614G mutation relative to Wuhan-Hu-1. Protein was produced in HEK293 cells and purified from culture supernatant by Protein G chromatography. |
|||
SARS-CoV-2 (A222V Mutant) Spike Glycoprotein (S1), Sheep Fc-Tag (HEK293) |
|||
| REC31932-100 | The Native Antigen Company | 0.1 | EUR 500.86 |
|
Description: SARS-CoV-2 Spike protein S1 containing A222V amino acid changes. |
|||
SARS-CoV-2 (A222V Mutant) Spike Glycoprotein (S1), Sheep Fc-Tag (HEK293) |
|||
| REC31932-500 | The Native Antigen Company | 0.5 | EUR 1903.02 |
|
Description: SARS-CoV-2 Spike protein S1 containing A222V amino acid changes. |
|||
SARS-CoV-2 (N439K Mutant) Spike Glycoprotein (S1), Sheep Fc-Tag (HEK293) |
|||
| REC31933-100 | The Native Antigen Company | 0.1 | EUR 500.86 |
|
Description: Recombinant SARS-CoV-2 spike subunit 1 protein containing N439K mutation. |
|||
SARS-CoV-2 (N439K Mutant) Spike Glycoprotein (S1), Sheep Fc-Tag (HEK293) |
|||
| REC31933-500 | The Native Antigen Company | 0.5 | EUR 1903.02 |
|
Description: Recombinant SARS-CoV-2 spike subunit 1 protein containing N439K mutation. |
|||
SARS Coronavirus Spike Glycoprotein (S2) Mosaic (C-Term) (E. coli) |
|||
| REC31841-100 | The Native Antigen Company | 0.1 | EUR 415.88 |
|
Description: Recombinant protein manufactured in E. coli. Contains the C-terminal section of the Spike protein immunodominant regions. Immunoreactive with sera from SARS-infected individuals. |
|||
SARS Coronavirus Spike Glycoprotein (S2) Mosaic (C-Term) (E. coli) |
|||
| REC31841-500 | The Native Antigen Company | 0.5 | EUR 1560.53 |
|
Description: Recombinant protein manufactured in E. coli. Contains the C-terminal section of the Spike protein immunodominant regions. Immunoreactive with sera from SARS-infected individuals. |
|||
SARS-CoV-2 Spike Glycoprotein (S1), Sheep Fc-Tag (HEK293) HRP conjugated |
|||
| BSV-COV-PR-28 | BioServUK | 100 ug | EUR 1079 |
|
Description: SARS-CoV-2 Spike Glycoprotein (S1), Sheep (Fc-Tag) (HEK293) (HRP-conjugated) |
|||
Novel Coronavirus Spike Glycoprotein RBD (SARS-CoV-2 S1 RBD) ELISA Kit |
|||
| MBS7135998-10x96StripWells | MyBiosource | 10x96-Strip-Wells | EUR 5325 |
Novel Coronavirus Spike Glycoprotein RBD (SARS-CoV-2 S1 RBD) ELISA Kit |
|||
| MBS7135998-24StripWellsLIMIT1 | MyBiosource | 24-Strip-Wells(LIMIT1) | EUR 275 |
Novel Coronavirus Spike Glycoprotein RBD (SARS-CoV-2 S1 RBD) ELISA Kit |
|||
| MBS7135998-48StripWells | MyBiosource | 48-Strip-Wells | EUR 480 |
Novel Coronavirus Spike Glycoprotein RBD (SARS-CoV-2 S1 RBD) ELISA Kit |
|||
| MBS7135998-5x96StripWells | MyBiosource | 5x96-Strip-Wells | EUR 2795 |
Novel Coronavirus Spike Glycoprotein RBD (SARS-CoV-2 S1 RBD) ELISA Kit |
|||
| MBS7135998-96StripWells | MyBiosource | 96-Strip-Wells | EUR 675 |
SARS-CoV-2 Spike Glycoproteins (S2), Sheep Fc-Tag (HEK293/CHO Cell Duo Pack) |
|||
| REC31968-DUO-100 | The Native Antigen Company | 0.1 | EUR 800.86 |
|
Description: Pack contains recombinant SARS-CoV-2 Spike S2 proteins manufactured in both HERK293 and CHO cells. |
|||
SARS-CoV-2 Spike Glycoproteins (S2), Sheep Fc-Tag (HEK293/CHO Cell Duo Pack) |
|||
| REC31968-DUO-500 | The Native Antigen Company | 0.5 | EUR 3045.09 |
|
Description: Pack contains recombinant SARS-CoV-2 Spike S2 proteins manufactured in both HERK293 and CHO cells. |
|||
SARS-CoV-2 Spike Glycoprotein (S1) RBD, His-Tag (HEK293): Biotin Conjugate |
|||
| REC31882-Biotin-100 | The Native Antigen Company | 0.1 | EUR 506.01 |
|
Description: SARS-CoV-2 Spike protein receptor binding domain (RBD) produced in HEK293 cells. The protein was purified from culture supernatant by immobilised metal affinity chromatography and conjugated to biotin. |
|||
SARS-CoV-2 (B.1.1.529/Omicron) Spike Glycoprotein (S1) RBD, His-Tag (HEK293) |
|||
| REC32007-100 | The Native Antigen Company | 0.1 | EUR 423.61 |
|
Description: Recombinant SARS-CoV-2 Omicron variant Spike receptor binding domain protein. Relative to Wuhan-Hu-1 this protein has following amino acid changes: G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H. |
|||
SARS-CoV-2 (B.1.1.529/Omicron) Spike Glycoprotein (S1) RBD, His-Tag (HEK293) |
|||
| REC32007-500 | The Native Antigen Company | 0.5 | EUR 1614.6 |
|
Description: Recombinant SARS-CoV-2 Omicron variant Spike receptor binding domain protein. Relative to Wuhan-Hu-1 this protein has following amino acid changes: G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H. |
|||
SARS-CoV-2 Spike Glycoprotein (Full-Length), His-Tag (CHO): HRP Conjugate |
|||
| REC31868-HRP-100 | The Native Antigen Company | 0.1 | EUR 730.05 |
|
Description: Recombinant full-length Spike protein (soluble domain). The furin cleavage site (AA 682-685) has been mutated from RRAR to SRAS and the transmembrane domain and intravirion part was replaced with a glycine-serine linker and a His-tag. Conjugated to Horseradish Peroxidase (HRP). |
|||
SARS-CoV-2 (B.1.1.529/Omicron) Spike Glycoprotein (S1), Sheep Fc-Tag (HEK293) |
|||
| REC32006-100 | The Native Antigen Company | 0.1 | EUR 500.86 |
|
Description: Recombinant SARS-CoV-2 (Omicron variant) Spike glycoprotein S1. Relative to Wuhan-Hu-1 the protein contains following amino acid changes: A67V, H69del, V70del, T95I, G142D, V143del, Y144del, Y145del, N211del, L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y. |
|||
SARS-CoV-2 (B.1.1.529/Omicron) Spike Glycoprotein (S1), Sheep Fc-Tag (HEK293) |
|||
| REC32006-500 | The Native Antigen Company | 0.5 | EUR 1903.02 |
|
Description: Recombinant SARS-CoV-2 (Omicron variant) Spike glycoprotein S1. Relative to Wuhan-Hu-1 the protein contains following amino acid changes: A67V, H69del, V70del, T95I, G142D, V143del, Y144del, Y145del, N211del, L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y. |
|||
